Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: A meta-analysis of pooled data from 14 clinical trials

Alberico Catapano, William E. Brady, Thomas R. King, Joanne Palmisano

Research output: Contribution to journalArticle

Abstract

Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.

Original languageEnglish
Pages (from-to)1123-1130
Number of pages8
JournalCurrent Medical Research and Opinion
Volume21
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Simvastatin
Meta-Analysis
Clinical Trials
Lipids
Therapeutics
Cholesterol
Rosuvastatin Calcium
Ezetimibe
Hyperlipoproteinemia Type II
Information Storage and Retrieval
Apolipoprotein A-I
Apolipoproteins B
Hypercholesterolemia
Hyperlipidemias
PubMed
Triglycerides
Pharmacokinetics
Databases

Keywords

  • Ezetimibe
  • Hypercholesterolemia
  • Lipids
  • Meta-analysis
  • Statin therapies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin : A meta-analysis of pooled data from 14 clinical trials. / Catapano, Alberico; Brady, William E.; King, Thomas R.; Palmisano, Joanne.

In: Current Medical Research and Opinion, Vol. 21, No. 7, 07.2005, p. 1123-1130.

Research output: Contribution to journalArticle

@article{285a741b9bb749a49be5d4b5bb27c22a,
title = "Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: A meta-analysis of pooled data from 14 clinical trials",
abstract = "Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2{\%} and 41.8{\%} for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6{\%} and 47.4{\%} for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9{\%} and 52.1{\%} for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7{\%} and 58.5{\%} for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.",
keywords = "Ezetimibe, Hypercholesterolemia, Lipids, Meta-analysis, Statin therapies",
author = "Alberico Catapano and Brady, {William E.} and King, {Thomas R.} and Joanne Palmisano",
year = "2005",
month = "7",
doi = "10.1185/030079905X50642",
language = "English",
volume = "21",
pages = "1123--1130",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin

T2 - A meta-analysis of pooled data from 14 clinical trials

AU - Catapano, Alberico

AU - Brady, William E.

AU - King, Thomas R.

AU - Palmisano, Joanne

PY - 2005/7

Y1 - 2005/7

N2 - Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.

AB - Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.

KW - Ezetimibe

KW - Hypercholesterolemia

KW - Lipids

KW - Meta-analysis

KW - Statin therapies

UR - http://www.scopus.com/inward/record.url?scp=22744436166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744436166&partnerID=8YFLogxK

U2 - 10.1185/030079905X50642

DO - 10.1185/030079905X50642

M3 - Article

C2 - 16004682

AN - SCOPUS:22744436166

VL - 21

SP - 1123

EP - 1130

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 7

ER -